Search
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIn clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046]. … It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.
Warfarin
go.drugbank.com/drugs/DB00682ApprovedInvestigationalWarfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. … Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America.
Categories: Compounds used in a research, industrial, or household settingDanaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnThe use of Orgaran™ was discontinued in the United States however it is available in several other countries including European countries and Japan. … Danaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously.
Mepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnIt has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. … Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.
Rubidium Rb-82
go.drugbank.com/drugs/DB09479ApprovedInvestigationalIt is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected … Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride.
Vernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Omaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigational[L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Synonyms: Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawna 68% reduction in the risk of death were observed. … [A262829] Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells
Oliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigationalSevere acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. … [A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by
Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. … Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.